A case of surgical treatment after steroid therapy for early onset sclerosing encapsulating peritonitis in patient undergoing continuous ambulatory peritoneal dialysis (CAPD).
- Author:
Yu Min LEE
1
;
Sung Won JUNG
;
Geom Seog SEO
;
Seung Hoon BAEK
;
Seon Ho AHN
;
Ju Hung SONG
;
Won Cheol PARK
Author Information
1. Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, Korea. ashneph@wmc.wonkwang.ac.kr
- Publication Type:Case Report
- Keywords:
Sclerosing encapsulating peritonitis;
Peritoneal dialysis
- MeSH:
Abdominal Pain;
Anorexia;
Azathioprine;
Constipation;
Diarrhea;
Fever;
Gastrointestinal Motility;
Humans;
Ileus;
Immunosuppression;
Nausea;
Peritoneal Dialysis;
Peritoneal Dialysis, Continuous Ambulatory*;
Peritoneal Fibrosis;
Peritonitis*;
Prognosis;
Vomiting;
Weight Loss
- From:Korean Journal of Medicine
2004;67(Suppl 3):S781-S787
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sclerosing encapsulating peritonitis (SEP) is the peritoneal thickness including the state of peritoneal fibrosis resulting from peritoneal inflammatory process of multifactorial etiologies. The symptoms and signs related to SEP include anorexia, nausea, vomiting, diarrhea, constipation, abdominal distension, fever, weight loss, abdominal pain and partial or intermittent bowel obstruction resulting from disturbance of the intestinal motility by the peritoneal sclerosis. The choice of management is considered as conservative treatment. However, if surgical intervention is necessary, the prognosis after surgery is usually poor. Recently, a few reports have suggested that immunosuppression (cyclophosphamide, azathioprine (100~125 mg), colchicine) and/or corticosteroid (30~50 mg) therapy might be effective in the treatment of SEP. We report a case of SEP that developed earlier than previous reported cases in patient undergoing continuous ambulatory peritoneal dialysis (CAPD) and report the surgical treatment of SEP which responded to steroid therapy thereafter symptoms by mechanical ileus were recurred.
